Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

ConferencepositivezorevunersenPositive

AI Analysis

Summary

Stoke Therapeutics and Biogen presented 4-year Phase 1/2a open-label extension data for zorevunersen showing substantial and durable seizure reductions with improvements in cognition and behavior in Dravet Syndrome patients at the 16th European Epilepsy Congress.

Clinical Trial Data

Phase

Phase 1/2a

Primary Endpoint

Met

Outcome Details

4-year Phase 1/2a OLE data showed substantial and durable seizure reductions with continuing improvements in cognition and behavior

Importance:6/10

Sentiment:

0.75

Dravet Syndromeclinical datalong-term efficacyseizure reductioncognitionopen-label extension

Related Companies

$BIIB

Read the original article

Published by GlobeNewswire Clinical Studies on September 3, 2026 11:30 PM

Read Original